This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
counselling (n=52) or antidepressant drugs (n=51). Another 220 patients refused randomisation but chose their treatment: 80 in the antidepressant group and 140 in the counselling group. The patients' demographic and disease characteristics were reported for each study group.
Study design
The study was a prospective randomised controlled trial that was conducted in a general practice setting. The patients were randomly selected from 410 general practices in the Trent health region. In the randomised arm of the study, treatment was allocated by telephone and the randomisation strategy used blocks of four stratified by practice. The follow-up period was 12 months. The patients were randomised to either counselling or antidepressants. Patients refusing randomisation, but agreeing to participate in the patient preference trial, were given the treatment of their choice. The psychiatrist assessing the main outcome measure was blinded to the treatment allocation. The number of patients who completed the 12-month questionnaire was 34 in the antidepressant group and 31 in the counselling group among those randomised, and 46 (antidepressant group) and 137 (counselling group), respectively, among those not randomised.
Analysis of effectiveness
The basis of the primary analysis was treatment completers only. The sensitivity analysis included assumed values for randomised patients without outcome data, caused mostly by the patients' non-attendance at the 12-month general practitioner (GP) follow-up. The main outcome measures at 12 months were:
the Beck depression inventory score, as completed by the patient; the time to remission, defined as an RDC score of less than 4 and a Beck score of less than 10; the global outcome, classified as good, moderate, poor or unknown, as assessed by a psychiatrist blinded to the treatment allocation; the RDC completed by the GP.
The global outcome was assessed using the RDC, Beck score and GP notes.
Some secondary outcomes were also assessed, but there were not relevant for the current economic evaluation.
The study groups were generally balanced at baseline. However, the patients who preferred counselling were less severely depressed than randomised patients or those who preferred antidepressants.
Effectiveness results
There were no statistically significant differences in any of the outcome measures used in the effectiveness analysis. The analysis also demonstrated that more patients opted for counselling.
Clinical conclusions
The authors concluded that the two treatments were equally effective for the treatment of patients with major depression.
Measure of benefits used in the economic analysis
The summary benefit measure was the psychiatrist's assessment of the global outcome, which was derived from the effectiveness study. inpatient hospital stays and psychiatric outpatient hospital visits. All GP consultations, drugs prescribed and use of GParranged counselling were recorded from the patients' notes. Hospital psychiatric outpatient and inpatient visits were abstracted from case notes. The unit costs were obtained from a published study (Netten et al., see Other Publications of Related Interest), the British National Formulary and invoices from counsellors in the trial. The quantities were derived directly from the effectiveness study. The costs and the quantities were not reported separately. Discounting was unnecessary. The price year was not reported.
Statistical analysis of costs
The analysis of cost data included measures of location (mean and median), variability (interquartile range), shape of distribution (skew: coefficient of asymmetry of information) and precision (95% confidence intervals). Inferences were based on a comparison of arithmetic means given by the t-test and the non-parametric Mann-Whitney U-test.
Indirect Costs
The indirect costs were not included in the analysis.
Currency
UK pounds sterling ().
Sensitivity analysis
A sensitivity analysis was conducted using assumed values for randomised patients without outcome data. The two scenarios considered were all missing patients achieved good global outcome and all missing patients achieved poor global outcome. The authors used the bootstrapping technique to confirm the validity of the results, based on a comparison of the mean costs using the standard t-test, and to account for possible sampling errors and to recognise uncertainty around the cost and effect data. A total of 2,000 iterations of resampled estimates were used in the simulation.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
There was no significant difference between the two randomised treatment groups in the cost of all depression-related health care for the 12 months following entry to the trial.
There was a significant cost-difference (counselling plus antidepressants) between the treatment groups when using the non-parametric test, 89.57 in the antidepressant group versus 115.92 in the counselling group, (p=0.031). There were also significantly higher GP depression-related consultation costs in the antidepressant group (70.20) versus the counselling group (56.54), (p=0.025).
For patients choosing their treatment modality, there was a significant difference between counselling and antidepressant groups in terms of the overall cost of depression-related health services. These costs were 335.63 (counselling group) and 263.41 (antidepressant group), respectively, when using the non-parametric test, (p=0.005).
No significant overall cost-differences between the randomised and patient preference groups were observed.
Synthesis of costs and benefits
Using conventional analysis, the authors found no significant difference between randomised treatment groups in either the outcomes or costs at 12 months.
